Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Urology,Oncology
Link
https://www.nature.com/articles/s41391-021-00381-w.pdf
Reference95 articles.
1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl J Med. 2010;363:411–22.
2. Madan RA, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, et al. Putting the pieces together: completing the mechanism of action jigsaw for Sipuleucel-T. J Natl Cancer Inst. 2020;112:562–73.
3. DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med. 2006;4:1.
4. Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res. 2006;12:3394–401.
5. Goldman B, DeFrancesco L. The cancer vaccine roller coaster. Nat Biotechnol. 2009;27:129–39.
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advancements and challenges in immunocytokines: A new arsenal against cancer;Acta Pharmaceutica Sinica B;2024-08
2. Contemporary Approaches to Immunotherapy of Solid Tumors;Cancers;2024-06-19
3. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer;Cancer Biology & Therapy;2024-05-27
4. Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes;Prostate Cancer and Prostatic Diseases;2024-02-28
5. Tumor-associated antigen targets for novel immune-based strategies in prostate cancer;Journal of Translational Genetics and Genomics;2024-02-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3